High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
3.49B
+8.2%
4.171
+5.86%
3.52B
+7.37%
4.069
+16.25%
3.55B
+6.58%
3.977
+15.29%
Estimates Revision
The market is revising Downward the revenue expectations for Labcorp Holdings Inc. (LH) for FY2025, with the revenue forecasts being adjusted by -0.21% over the past three months. During the same period, the stock price has changed by 9.04%.
Revenue Estimates for FY2025
Revise Downward
-0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.39%
In Past 3 Month
Stock Price
Go Up
+9.04%
In Past 3 Month
12 Analyst Rating
0Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 276.27 USD with a low forecast of 250.00 USD and a high forecast of 291.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
0Current: 261.390
Low
250.00
Averages
276.27
High
291.00
0Current: 261.390
Low
250.00
Averages
276.27
High
291.00
Morgan Stanley
Erin Wright
Overweight
maintain
$270 -> $283
2025-06-11
Reason
Morgan Stanley
Erin Wright
Price Target
$270 -> $283
2025-06-11
maintain
Overweight
Reason
Morgan Stanley analyst Erin Wright raised the firm's price target on Labcorp to $283 from $270 and keeps an Overweight rating on the shares. After having hosted a call with the company's CEO and CFO, the firm walked away "bullish" on Labcorp's growth prospects in what the executives characterized as "a new, higher level of core utilization," the analyst tells investors. While making no changes to underlying growth assumptions at this point, the firm is raising its target price to reflect greater conviction in the company's growth prospects in light of a more durable utilization backdrop, the analyst added.
Truist
David MacDonald
maintain
$274 -> $290
2025-05-12
Reason
Truist
David MacDonald
Price Target
$274 -> $290
2025-05-12
maintain
Reason
Truist analyst David MacDonald raised the firm's price target on Labcorp to $290 from $274 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Truist Securities
David Macdonald
Strong Buy
Maintains
$285 → $274
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$285 → $274
2025-04-11
Maintains
Strong Buy
Reason
Truist lowered the firm's price target on Labcorp to $274 from $285 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
Barclays
Jack Meehan
Hold
Maintains
$260 → $240
2025-04-10
Reason
Barclays
Jack Meehan
Price Target
$260 → $240
2025-04-10
Maintains
Hold
Reason
Barclays analyst Luke Sergott lowered the firm's price target on Labcorp to $240 from $260 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.
Redburn Atlantic
Jamie Clark
Strong Buy
Initiates
$276
2025-04-02
Reason
Redburn Atlantic
Jamie Clark
Price Target
$276
2025-04-02
Initiates
Strong Buy
Reason
Redburn Atlantic initiated coverage of Labcorp with a Buy rating and $276 price target.
Citigroup
Ralph Giacobbe
Hold
to
Strong Buy
Upgrades
$250 → $300
2025-03-04
Reason
Citigroup
Ralph Giacobbe
Price Target
$250 → $300
2025-03-04
Upgrades
Hold
to
Strong Buy
Reason
Citi upgraded Labcorp to Buy from Neutral with a price target of $300, up from $250. Utilization rates have been running high post-pandemic with no signs of slowing down and Labcorp is well positioned to capitalize on that through its core diagnostics business, the analyst tells investors in a research note. The firm says that while the recent Invitae acquisition will enter fiscal 2025 dilutive to margin, there is line of sight to breakeven and even accretion. Further, after multiple quarters of headwinds within Labcorp's Early Development business, a gradual recovery seems to be materializing which should ease some of the overhang on the stock, contends Citi.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Labcorp Holdings Inc (LH.N) is 15.62, compared to its 5-year average forward P/E of 13.90. For a more detailed relative valuation and DCF analysis to assess Labcorp Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
13.90
Current PE
15.62
Overvalued PE
16.37
Undervalued PE
11.44
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
10.31
Current EV/EBITDA
11.45
Overvalued EV/EBITDA
11.78
Undervalued EV/EBITDA
8.84
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
1.53
Current PS
1.52
Overvalued PS
1.74
Undervalued PS
1.32
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 676.52% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
LH News & Events
Events Timeline
(ET)
2025-06-12
08:36:04
Predictive Oncology develops functional 3D organoid models for Labcorp
2025-05-30 (ET)
2025-05-30
07:06:21
Labcorp expands precision oncology portfolio
2025-05-23 (ET)
2025-05-23
17:24:52
Labcorp awarded $117.03M Army contract modification
Sign Up For More Events
Sign Up For More Events
News
Preview
5.0
06-19NASDAQ.COMLabcorp Unveils Whole Health Solutions For Functional And Integrative Medicine Providers
Preview
5.0
06-18NewsfilterLabcorp Launches Labcorp Whole Health Solutions to Support Holistic Care
Preview
3.5
06-12NewsfilterPredictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
Sign Up For More News
People Also Watch
FAQ
What is Labcorp Holdings Inc (LH) stock price today?
What is Labcorp Holdings Inc (LH)'s business?
What is the price predicton of LH Stock?
What is Labcorp Holdings Inc (LH)'s revenue for the last quarter?
What is Labcorp Holdings Inc (LH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Labcorp Holdings Inc (LH)'s fundamentals?
How many employees does Labcorp Holdings Inc (LH). have?